Bowel Preparation Before Colonoscopy Clinical Trial
Official title:
A Prospective, Randomized Controlled Clinical Study of the Efficacy and Safety of Bowklean and Klean-Prep With Dulcolax for the Bowel Preparation Prior Colonoscopy
The primary objective of this study is to demonstrate that investigation medication
(Bowklean) is not less effective than the active comparator (Klean-Prep with Dulcolax), with
regards to the overall quality of bowel preparation in subjects undergoing colonoscopy. An
additional objective of this study is to collect subject's response to the acceptability and
tolerability about bowel preparation and safety information.
After bowel preparation, independent evaluator who is blinded to subject's treatment will
evaluate the overall colon cleansing based on Aronchick and Ottawa scale. A total of 600
eligible subjects scheduled to a colonoscopy will be randomly assigned with equal allocation
to 1 of 2 treatment groups: "Bowklean" or "Klean-Prep" with Dulcolax. Each subject's
participation is expected to be maximally 4 weeks in study duration (up to 3-week screening
period followed by one week post colonoscopy).
The objective of this study was to demonstrate that investigational medication (Bowklean) is
not less effective than the active comparator (Klean-Prep with Dulcolax), with regards to the
overall quality of bowel preparation in subjects undergoing colonoscopy. It was designed to
measure the number of subjects whose colons are cleansed successfully.
The primary efficacy endpoint is the percentage of subjects that achieve excellent or good
cleansing (success rate) in the Aronchick Scale.
The secondary efficacy variables include:
1. Proportion of successes (excellent, good, or fair) by individual colon segment
(ascending, transverse, descending), which are assessed with the Ottawa scale6.
2. Mean bowel preparation score assessed with Ottawa Scale by adding points for the
cleansing of three parts of colon and points for amount of fluid in the bowel.
3. Percentage of subject's responses to the acceptability and tolerability
Safety was assessed at each clinic visit by evaluation of the following variables:
1. Percentage of subjects occurred solicited event (nausea, vomiting, chest pain and
dizziness) during the preparation.
2. Percentage of subjects with treatment-emergent adverse events during the study period.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05498714 -
Improved Bowel Cleansing Method for Colonoscopy Based on High Risk Population of Bowel Preparation
|
N/A | |
| Completed |
NCT01745835 -
Comparison Between 2L Coolprep® and Combination of 1L Coolprep® and Bisacodyl as Bowel Preparation
|
Phase 3 | |
| Completed |
NCT02910440 -
A Safety and Efficacy Study of DCL-101 Compared to GoLYTELY
|
Phase 2 | |
| Recruiting |
NCT05054036 -
MoviPrep® Versus GoLYTELY® Bowel Preparation in Hospitalized Patients Undergoing Colonoscopy
|
Phase 4 | |
| Completed |
NCT04582942 -
Improved Bowel Preparation Method for Colonoscopy Based on Different Risk Stratification
|
N/A | |
| Recruiting |
NCT03106922 -
A Trial to Evaluate the Efficacy and Safety of PMF104 Compared to a Conventional PEG-electrolyte Solution in Children
|
Phase 3 |